Solventum (NYSE:SOLV) Reaches New 1-Year High on Earnings Beat

Key Points

• Solventum beat quarterly expectations: Adjusted EPS came in at $2.55 versus the $1.91 consensus, while revenue reached $2.21 billion, ahead of the $2.15 billion estimate. Shares touched a new 52-week high of $90.
• Fiscal 2026 guidance was raised: The company now expects adjusted EPS of $7.10–$7.20, alongside improved forecasts for organic sales growth and free cash flow.
• Health Information Systems separation adds potential and risk: Solventum plans to spin off its healthcare software business to focus on MedTech, but investors face uncertainty around timing, restructuring costs and execution. Analysts’ consensus rating remains “Hold,” with an average price target of $88.91.

Solventum Corporation (NYSE:SOLV - Get Free Report)'s share price reached a new 52-week high on Thursday following a stronger than expected earnings report. The company traded as high as $90.00 and last traded at $85.2360, with a volume of 103667 shares changing hands. The stock had previously closed at $87.47.

The company reported $2.55 earnings per share for the quarter, beating analysts' consensus estimates of $1.91 by $0.64. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. During the same quarter in the previous year, the firm posted $1.69 EPS. The company's revenue for the quarter was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS.

Key Headlines Impacting Solventum

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Quarterly results exceeded expectations. Solventum reported second-quarter adjusted earnings of $2.55 per share, well above the $1.91 analyst consensus and up from $1.69 a year earlier. Revenue reached $2.21 billion, topping the $2.15 billion estimate, while reported sales rose 2.2% and organic sales increased 9.5%. Solventum Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year guidance was raised. Solventum increased its fiscal 2026 adjusted EPS outlook to $7.10-$7.20, above the roughly $6.55-$6.58 analyst expectation, while also raising its outlook for organic sales growth and free cash flow. Solventum outlines HIS separation and raises 2026 EPS guide
• Positive Sentiment: The HIS separation could unlock value. Management said it intends to separate its healthcare software business, allowing Solventum to focus on MedTech while giving HIS greater flexibility to pursue investment and growth as a standalone company. Solventum Announces Intent to Separate its Health Information Systems Business
• Negative Sentiment: Investors may be concerned about separation and execution risks. The HIS transaction, reportedly influenced by activist pressure, adds restructuring complexity and uncertainty over timing, costs, stranded expenses and the eventual value of the separated businesses. Solventum to hive off healthcare software business, raises profit forecast

Wall Street Analysts Forecast Growth

Several research firms recently commented on SOLV. Mizuho set a $113.00 price objective on shares of Solventum in a research note on Thursday. Wedbush started coverage on shares of Solventum in a research note on Friday, May 15th. They issued an "outperform" rating and a $94.00 target price on the stock. Stifel Nicolaus reduced their price target on shares of Solventum from $105.00 to $90.00 and set a "buy" rating for the company in a research report on Wednesday, May 6th. Piper Sandler decreased their price objective on shares of Solventum from $98.00 to $92.00 and set an "overweight" rating for the company in a report on Friday, April 17th. Finally, BTIG Research increased their target price on Solventum from $91.00 to $95.00 and gave the company a "buy" rating in a research note on Thursday. Seven investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Solventum currently has a consensus rating of "Hold" and an average price target of $88.91.

Hedge Funds Weigh In On Solventum

A number of institutional investors and hedge funds have recently modified their holdings of the company. CrossGen Wealth LLC bought a new stake in shares of Solventum during the 4th quarter valued at about $25,000. Measured Wealth Private Client Group LLC purchased a new position in shares of Solventum in the third quarter worth approximately $25,000. Clearstead Trust LLC grew its position in Solventum by 61.0% during the first quarter. Clearstead Trust LLC now owns 396 shares of the company's stock valued at $26,000 after buying an additional 150 shares during the period. JNBA Financial Advisors increased its holdings in Solventum by 205.4% during the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company's stock valued at $27,000 after buying an additional 228 shares during the last quarter. Finally, CYBER HORNET ETFs LLC bought a new position in Solventum in the second quarter worth approximately $28,000.

Solventum Stock Down 3.5%

The company's 50 day moving average price is $79.09 and its two-hundred day moving average price is $74.36. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96. The firm has a market cap of $14.62 billion, a PE ratio of 10.35, a PEG ratio of 1.36 and a beta of 0.60.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source